Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inmune Bio (INMB) EBIT (2018 - 2025)

Inmune Bio's EBIT history spans 8 years, with the latest figure at -$7.4 million for Q3 2025.

  • For Q3 2025, EBIT rose 39.5% year-over-year to -$7.4 million; the TTM value through Sep 2025 reached -$51.4 million, down 23.66%, while the annual FY2024 figure was -$42.6 million, 43.35% down from the prior year.
  • EBIT for Q3 2025 was -$7.4 million at Inmune Bio, up from -$24.6 million in the prior quarter.
  • Across five years, EBIT topped out at -$4.5 million in Q1 2021 and bottomed at -$24.6 million in Q2 2025.
  • The 5-year median for EBIT is -$8.4 million (2023), against an average of -$8.9 million.
  • The largest annual shift saw EBIT crashed 211.06% in 2021 before it surged 39.5% in 2025.
  • A 5-year view of EBIT shows it stood at -$9.0 million in 2021, then surged by 37.52% to -$5.6 million in 2022, then tumbled by 48.51% to -$8.4 million in 2023, then decreased by 12.98% to -$9.5 million in 2024, then grew by 21.49% to -$7.4 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's EBIT are -$7.4 million (Q3 2025), -$24.6 million (Q2 2025), and -$9.9 million (Q1 2025).